vs
Side-by-side financial comparison of Leslie's, Inc. (LESL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $147.1M, roughly 1.2× Leslie's, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -56.4%, a 58.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -16.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -11.7%).
Leslie's, Inc., operating as Leslie's Swimming Pool Supplies, is the largest retailer of swimming pool supplies and related products. The company is headquartered in Phoenix, Arizona, and has a particularly strong retail presence in Arizona, California, Florida, Georgia and Texas.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LESL vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $147.1M | $177.4M |
| Net Profit | $-83.0M | $2.9M |
| Gross Margin | 18.4% | — |
| Operating Margin | -46.7% | 3.9% |
| Net Margin | -56.4% | 1.6% |
| Revenue YoY | -16.0% | 5.0% |
| Net Profit YoY | -86.2% | — |
| EPS (diluted) | $-8.92 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $147.1M | $177.4M | ||
| Q4 25 | $389.2M | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $500.3M | $181.1M | ||
| Q1 25 | $177.1M | $168.9M | ||
| Q4 24 | $175.2M | $187.3M | ||
| Q3 24 | $397.9M | $168.6M | ||
| Q2 24 | $569.6M | $178.0M |
| Q1 26 | $-83.0M | $2.9M | ||
| Q4 25 | $-162.8M | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $21.7M | $-4.8M | ||
| Q1 25 | $-51.3M | $4.8M | ||
| Q4 24 | $-44.6M | — | ||
| Q3 24 | $-9.9M | $-143.5M | ||
| Q2 24 | $60.6M | $18.9M |
| Q1 26 | 18.4% | — | ||
| Q4 25 | 38.6% | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 39.6% | 77.4% | ||
| Q1 25 | 24.8% | 79.7% | ||
| Q4 24 | 27.2% | 78.7% | ||
| Q3 24 | 36.0% | 76.9% | ||
| Q2 24 | 40.2% | 75.1% |
| Q1 26 | -46.7% | 3.9% | ||
| Q4 25 | -38.6% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | 13.7% | 4.7% | ||
| Q1 25 | -27.3% | 1.2% | ||
| Q4 24 | -22.7% | 13.2% | ||
| Q3 24 | 6.6% | -82.8% | ||
| Q2 24 | 17.2% | 15.9% |
| Q1 26 | -56.4% | 1.6% | ||
| Q4 25 | -41.8% | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 4.3% | -2.7% | ||
| Q1 25 | -29.0% | 2.8% | ||
| Q4 24 | -25.4% | — | ||
| Q3 24 | -2.5% | -85.1% | ||
| Q2 24 | 10.6% | 10.6% |
| Q1 26 | $-8.92 | $0.07 | ||
| Q4 25 | $-20.59 | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $0.12 | $-0.11 | ||
| Q1 25 | $-0.28 | $0.10 | ||
| Q4 24 | $-4.82 | $0.38 | ||
| Q3 24 | $-2.46 | $-3.11 | ||
| Q2 24 | $0.33 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6M | $144.3M |
| Total DebtLower is stronger | $781.6M | — |
| Stockholders' EquityBook value | $-489.9M | $653.9M |
| Total Assets | $649.4M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.6M | $144.3M | ||
| Q4 25 | $64.3M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $42.7M | $445.9M | ||
| Q1 25 | $17.3M | $493.6M | ||
| Q4 24 | $11.6M | $484.6M | ||
| Q3 24 | $108.5M | $453.8M | ||
| Q2 24 | $74.4M | $404.2M |
| Q1 26 | $781.6M | — | ||
| Q4 25 | $756.6M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $776.6M | $580.5M | ||
| Q1 25 | $858.1M | $583.4M | ||
| Q4 24 | $796.6M | $585.3M | ||
| Q3 24 | $783.7M | — | ||
| Q2 24 | $783.7M | — |
| Q1 26 | $-489.9M | $653.9M | ||
| Q4 25 | $-408.0M | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | $-246.2M | $757.8M | ||
| Q1 25 | $-269.5M | $798.5M | ||
| Q4 24 | $-220.0M | $778.3M | ||
| Q3 24 | $-177.1M | $749.6M | ||
| Q2 24 | $-168.2M | $879.3M |
| Q1 26 | $649.4M | $1.2B | ||
| Q4 25 | $741.5M | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $989.5M | $1.5B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $967.0M | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-81.1M | — |
| Free Cash FlowOCF − Capex | $-85.5M | — |
| FCF MarginFCF / Revenue | -58.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-81.1M | — | ||
| Q4 25 | $48.2M | $43.7M | ||
| Q3 25 | — | $60.8M | ||
| Q2 25 | $114.9M | $12.0M | ||
| Q1 25 | $-49.2M | $35.5M | ||
| Q4 24 | $-105.1M | $33.1M | ||
| Q3 24 | $47.1M | $53.9M | ||
| Q2 24 | $175.5M | $53.2M |
| Q1 26 | $-85.5M | — | ||
| Q4 25 | $41.8M | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | $107.1M | $9.3M | ||
| Q1 25 | $-55.8M | $26.9M | ||
| Q4 24 | $-109.8M | $31.0M | ||
| Q3 24 | $34.1M | $49.8M | ||
| Q2 24 | $165.2M | $51.6M |
| Q1 26 | -58.1% | — | ||
| Q4 25 | 10.7% | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | 21.4% | 5.1% | ||
| Q1 25 | -31.5% | 15.9% | ||
| Q4 24 | -62.6% | 16.6% | ||
| Q3 24 | 8.6% | 29.6% | ||
| Q2 24 | 29.0% | 29.0% |
| Q1 26 | 2.9% | — | ||
| Q4 25 | 1.7% | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 3.7% | 5.1% | ||
| Q4 24 | 2.7% | 1.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 1.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.89× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LESL
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
